HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a Seoul-based, publicly listed biopharmaceutical company developing FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF (tanfanercept), a Nurr1 activator (HL192) and licensed epigenetic reprogramming technology, licensed globally via Immunovant, Daewoong, NurrOn and Turn Bio, alongside a Korean specialty pharma portfolio.
- Company typePublic
- Founded1973
- HeadquartersSeoul, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What HanAll Biopharma does
HanAll Biopharma Co., Ltd. (KRX: 009420.KS) is a Seoul-headquartered, publicly listed biopharmaceutical company founded in 1973 that develops innovative biologic medicines across ophthalmology, immunology, oncology, and neurology. Its pipeline is anchored by batoclimab (HL161) and the next-generation HL161ANS (IMVT-1402), both fully human subcutaneous antibodies targeting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG in autoimmune diseases including myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves' disease; HL161ANS is licensed to Immunovant for the US and Europe and is designed to minimize albumin and LDL perturbation. Tanfanercept (HL036) is a molecularly engineered topical TNFR1 fragment for dry eye disease, currently in the Phase 3 VELOS-4 study with Daewoong Pharmaceutical. HL192 (ATH-399A) is a Nurr1 activator co-developed with Daewoong and NurrOn Pharmaceuticals as a potential disease-modifying therapy for Parkinson's disease, having completed a 76-participant Phase 1 first-in-human study in 2024. HanAll also holds an exclusive license to Turn Biotechnologies' Epigenetic Reprogramming of Aging (ERATM) mRNA technology for ophthalmic and otic indications, with potential deal value exceeding US$300 million for the initial product, and is co-developing immuno-oncology assets HL187 (anti-TIGIT) and HL186 (anti-TIM-3) with Daewoong.
The company's revenue model combines direct sales of an established Korean pharmaceutical portfolio in endocrine, circulatory, and urologic therapeutic areas (133 billion KRW in 2025, 13% YoY growth, three consecutive years of double-digit growth) with licensing, milestone, and co-development receipts from global partners including Immunovant, Daewoong, NurrOn, and Turn Biotechnologies. Distribution is via traditional pharmaceutical channels in Korea and through licensed partners internationally; the company maintains offices in Seoul, Rockville (MD, USA), Osaka (Japan), and Indonesia. Revenue economics are increasingly tied to clinical and regulatory milestones across the FcRn franchise and the maturing ophthalmology and neurology programs, offset by an active cost base — operating profit was -0.9 billion KRW in 2025 and net income -5.6 billion KRW versus +3.5 billion KRW in 2023, reflecting elevated SG&A and R&D investment (over 10% of annual revenue).
Customer concentration is bimodal: a distributed base of Korean wholesalers, hospitals, and pharmacies absorbs the legacy pharmaceutical volume, while a small set of global licensing partners — principally Immunovant for US/European FcRn rights and Daewoong for co-developed assets — governs the long-term value realization of the pipeline. This concentration was sharpened by the termination of the Harbour BioMed Greater China license in March 2025 and by Immunovant's April 2026 Phase 3 failure of batoclimab in thyroid eye disease, both of which crystallize near-term execution risk on the company's most strategic licensing relationship.
HanAll Biopharma firmographics
Firmographics- Name
- HanAll Biopharma
- Legal name
- HanAll Biopharma Co., Ltd.
- Website
- https://hanall.com
- Company type
- Public
- Founded year
- 1973
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- HanAll Biopharma (KRX: 009420.KS) is a Seoul-based, publicly listed biopharmaceutical company developing FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF (tanfanercept), a Nurr1 activator (HL192) and licensed epigenetic reprogramming technology, licensed globally via Immunovant, Daewoong, NurrOn and Turn Bio, alongside a Korean specialty pharma portfolio.
- Ownership category
- akta.pro rank
HanAll Biopharma industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where HanAll Biopharma is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices6 records
Markets served
HanAll Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Sales of established pharmaceutical products including probiotics, hair loss treatments, and urology medications. Generated 133 billion KRW in pharmaceutical sales in 2025 with 13% year-over-year growth, marking three consecutive years of double-digit growth.
- Licensing and Milestone Payments: Revenue from licensing agreements including upfront payments, development milestones, and royalties from partners such as Immunovant for US/Europe and Harbour BioMed for China.
- Co-development and Collaboration Revenue: Revenue from co-development partnerships including milestone achievements from collaborations with Daewoong Pharmaceutical, NurrOn Pharmaceuticals, and other partners.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
HanAll Biopharma product offering
Product offeringCore offering
HanAll Biopharma is a global biopharmaceutical company that develops, manufactures, and commercializes innovative biologic therapies across four therapeutic areas — Ophthalmology, Immunology, Oncology, and Neurology. The company's commercial portfolio spans established prescription drugs (probiotics, hair loss, and urology medications) in Korean and Asian markets, while its R&D pipeline includes anti-FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF for dry eye disease (tanfanercept), a Nurr1 activator for Parkinson's (HL192), and immuno-oncology candidates (HL187, HL186). Revenue is generated through direct pharmaceutical sales in Korea and licensing/royalty agreements with global partners such as Immunovant and Daewoong Pharmaceutical.
Product overview
HanAll Biopharma is a global biopharmaceutical company focused on developing innovative therapies across four key therapeutic areas: Ophthalmology, Immunology, Oncology, and Neurology. The company's pipeline centers on novel biologic drugs including tanfanercept (anti-TNF for dry eye disease), batoclimab and HL161ANS (anti-FcRn antibodies for autoimmune diseases), HL192 (Nurr1 activator for Parkinson's), and immuno-oncology candidates (HL187 anti-TIGIT, HL186 anti-TIM-3). The company also holds an exclusive license to Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. HanAll operates alongside established commercial products in endocrine, circulatory, and urologic therapeutic areas with over 50 years of operating history.
Differentiator
Problem solved
Functional benefit
Products and services
- Batoclimab (HL161) A novel, fully human, subcutaneously administered antibody targeting the neonatal Fc receptor (FcRn), designed to selectively bind to FcRn to reduce levels of harmful IgG antibodies. Being developed for IgG-mediated autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Licensed to Immunovant for development and commercialization in the US and Europe.
- Tanfanercept (HL036) A novel, topical, anti-inflammatory treatment targeting tumor necrosis factor (TNF) for dry eye disease (DED). It is a molecularly engineered tumor necrosis factor receptor 1 (TNFR1) fragment with strong affinity for TNF and resistance to degradation by proteinases. Co-developed with Daewoong Pharmaceutical.
- HL161ANS (IMVT-1402) A next-generation anti-FcRn antibody designed to deliver maximum IgG reductions while minimizing interference with albumin recycling, demonstrating a potentially best-in-class profile with deep IgG reduction similar to batoclimab but with no or minimal changes in serum albumin and LDL-cholesterol level. Subcutaneous administration. Being advanced by Immunovant across multiple registrational studies.
- HL192 (ATH-399A) A Nurr1 activator developed as a potential disease-modifying therapy for Parkinson's disease. Nurr1 is a master regulator in dopaminergic neuron development and maintenance and an important component in anti-inflammatory functions. Co-developed with NurrOn Pharmaceuticals and Daewoong Pharmaceutical, in collaboration with Harvard Medical School.
- HL187 A monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains) being developed in collaboration with Daewoong Pharmaceutical as a potential immuno-oncology treatment.
- HL186 A monoclonal antibody targeting TIM-3 (T cell Ig and mucin domain-3) being developed in collaboration with Daewoong Pharmaceutical as a potential immuno-oncology treatment.
- Commercial pharmaceutical portfolio (probiotics, hair loss, urology) Established commercial pharmaceutical products sold in Korea and other regional markets addressing endocrine, circulatory, and urologic therapeutic areas, including probiotics, hair loss treatments, and urology medications. These products generated 133 billion KRW in sales in 2025 and have been the foundation of the company for over 50 years.
Quantifiable outcome
- Phase 3 MG study: met primary endpoint of mean change from baseline in MG-ADL in ACHR population at 12 weeks (680mg: 5.6, 340mg: 4.7, placebo: 3.6)
- +5 more outcomes
Companies that use HanAll Biopharma
Customer profileSegments4 records
Ideal customer profiles1 record
HanAll Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
HanAll Biopharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- NurrOn PharmaceuticalscoreCo-development partnership with Daewoong Pharmaceutical and NurrOn Pharmaceuticals for HL192 (ATH-399A), a Nurr1 activator for Parkinson's disease. Successfully completed Phase 1 first-in-human study demonstrating safety and tolerability in 76 healthy participants. NurrOn received $1.7 million grant from The Michael J. Fox Foundation for Parkinson's Research in support of the trial.
- Turn BiotechnologiescoreExclusive licensing agreement granting HanAll rights to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic diseases. Deal value can exceed $300 million USD for the initial product. Expands relationship from initial investment in 2022.
- Daewoong PharmaceuticalcoreCo-development agreement for tanfanercept (HL036) for dry eye disease. Daewoong and HanAll jointly conducting Phase 3 VELOS-4 study. Also co-development partner for HL192 (ATH-399A) for Parkinson's disease.
- GaluxminorCollaboration with Galux, an AI-powered antibody drug design company, as part of HanAll's AI platform expansion for antibody design and R&D infrastructure development.
Scale indicators14 records
Recent moves9 records
Expansion highlights5 records
HanAll Biopharma competitors and assessment
Company assessmentDirect peers
- argenx: argenx is the leading FcRn antibody developer (Vyvgart/efgartigimod) and the most direct competitor to HanAll's batoclimab and HL161ANS franchise in myasthenia gravis, CIDP, and other IgG-mediated autoimmune diseases.
- Immunovant: Immunovant is a Roivant subsidiary that licensed batoclimab from HanAll for US/Europe and is independently developing next-gen FcRn candidate IMVT-1402 (HL161ANS). Its registrational strategy and clinical readout cadence directly drive HanAll's milestone and royalty economics.
- UCB: UCB developed Rystiggo (rozanolixizumab), a subcutaneous FcRn antibody approved for myasthenia gravis, making it a direct FcRn competitor to HanAll's pipeline assets and a relevant comp for commercial trajectory in the same indication.
Regional players
- Celltrion: Celltrion is a major Korean biopharmaceutical company developing biosimilars and novel biologics, including autoimmune and ophthalmology assets. As a Korean-headquartered peer with similar listing profile and biologics manufacturing capabilities, it provides a direct regional comparable.
- Samsung Bioepis: Samsung Bioepis is a Korean biosimilars and biopharmaceutical company developing immunology and oncology biologics. Its Korean domicile, biologics platform, and pipeline overlap with HanAll's immunology focus make it a relevant regional comparable.
- Daewoong Pharmaceutical: Daewoong is a Korean pharmaceutical company and HanAll's co-development partner on tanfanercept (HL036), HL192 (ATH-399A), and immuno-oncology assets HL186/HL187. Comparable in therapeutic area focus (immunology, neurology, ophthalmology) and Korean listed-company profile.
- Yuhan Corporation: Yuhan is a top Korean pharmaceutical company with a diversified established-product portfolio and pipeline in immunology, oncology, and chronic disease. Comparable to HanAll on Korean listed-company profile, commercial scale in Korea, and pipeline breadth.
Broad incumbents
- AbbVie: AbbVie is a global immunology leader with Humira, Skyrizi, and Rinvoq across multiple autoimmune indications. As a broad incumbent in the same disease areas HanAll targets via FcRn antibodies, it shapes competitive and pricing dynamics for IgG-mediated disease therapies.
- Regeneron: Regeneron is a leading antibody platform company with Eylea in ophthalmology and a strong immunology pipeline. Comparable to HanAll on antibody-based innovation, biologics manufacturing, and large commercial partnerships (e.g., Sanofi/Bayer).
- Novartis: Novartis has a substantial ophthalmology franchise (Xiidra, Beovu) directly relevant to HanAll's tanfanercept dry eye program, and a growing immunology pipeline. Its commercial reach and R&D scale make it a key incumbent competitor across HanAll's focus areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
HanAll Biopharma social profiles
Digital presenceHanAll Biopharma compliance and trust
Trust signalCompliance2 records
HanAll Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
HanAll Biopharma leadership team
Management profileNumber of profiles
Profiles6 records
HanAll Biopharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HanAll Biopharma M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HanAll Biopharma
What does HanAll Biopharma do?
HanAll Biopharma is a global biopharmaceutical company that develops, manufactures, and commercializes innovative biologic therapies across four therapeutic areas — Ophthalmology, Immunology, Oncology, and Neurology. The company's commercial portfolio spans established prescription drugs (probiotics, hair loss, and urology medications) in Korean and Asian markets, while its R&D pipeline includes anti-FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF for dry eye disease (tanfanercept), a Nurr1 activator for Parkinson's (HL192), and immuno-oncology candidates (HL187, HL186). Revenue is generated through direct pharmaceutical sales in Korea and licensing/royalty agreements with global partners such as Immunovant and Daewoong Pharmaceutical.
Is HanAll Biopharma a public or private company?
HanAll Biopharma is a public company. It is classified as public and is currently operating.
When was HanAll Biopharma founded?
HanAll Biopharma was founded in 1973. It employs 101 to 250 people.
Where is HanAll Biopharma based?
HanAll Biopharma is headquartered in Seoul, South Korea, in the Asia region.
How does HanAll Biopharma make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Milestone Payments and co-development and Collaboration Revenue.
Who are HanAll Biopharma's main competitors?
Direct peers on record are argenx, Immunovant and UCB. Regional players are Celltrion, Samsung Bioepis, Daewoong Pharmaceutical and Yuhan Corporation. Broad incumbents are AbbVie, Regeneron and Novartis.
Does HanAll Biopharma have an API?
No public API is recorded for HanAll Biopharma.
What industry is HanAll Biopharma in?
HanAll Biopharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.